Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer

• Published in: British journal of cancer Vol. 106; no. 10; pp. 1591 - 1597
• Main Authors: Jo, J-C, Lee, J-L, Ryu, M-H, Chang, H M, Kim, M, Lee, H J, Kim, H-S, Shin, J-G, Kim, T-W, Kang, Y-K
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.05.2012; Nature Publishing Group
• Subjects: 631/92/436/434; 692/699/67/1059/99; 692/699/67/1504/1829; Adult; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - adverse effects; Biomedical and Life Sciences; Biomedicine; Camptothecin - administration & dosage; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Cancer Research; Cancer therapies; Cell division; Chemotherapy; Clinical Study; Drug dosages; Drug Resistance; Epidemiology; Female; Gastric cancer; Genotype; Genotype & phenotype; Glucuronosyltransferase - genetics; Hematology; Humans; Male; Medical research; Metastasis; Middle Aged; Molecular Medicine; Neutropenia; Oncology; Patients; Salvage Therapy; Stomach Neoplasms - drug therapy; Stomach Neoplasms - genetics; Stomach Neoplasms - mortality; Toxicity; irinotecan; gastric cancer; UDP-glucuronosyltransferase; salvage therapy; chemotherapy; genotype

Background: To assess the efficacy and safety of individualised dose optimisation of irinotecan monotherapy as salvage treatment for advanced gastric cancer (AGC). Methods: A total of 43 patients were enrolled. Intravenous irinotecan (350 mg m −2 ) was administered every 3 weeks. The dose was increa...